|
The role of c-Maf in Stem cells in Leukemia
|
5F31CA162770-04
|
$42,676
|
$21,338
|
OKOYE, UJUNWA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
IL-15 Superagonist Complex as an Immunotherapeutic for Multiple Myeloma
|
2R44CA167925-02
|
$750,000
|
$750,000
|
WONG, HING
|
ALTOR BIOSCIENCE CORPORATION
|
|
Sensitivity of multiple myeloma cells to mTOR inhibitors
|
5R01CA111448-08
|
$178,742
|
$178,742
|
LICHTENSTEIN, ALAN
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
|
Targeting DEPTOR in multiple myeloma
|
5R21CA168491-02
|
$168,780
|
$168,780
|
LICHTENSTEIN, ALAN
|
BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
1U10CA180821-01
|
$10,540,919
|
$263,523
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-01S1
|
$228,063
|
$5,702
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-01S2
|
$264,661
|
$6,617
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-01S3
|
$16,838
|
$421
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Bcl-2 function on the endoplasmic reticulum
|
5R01CA085804-15
|
$275,915
|
$55,183
|
DISTELHORST, CLARK
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-24S1
|
$74,051
|
$2,962
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-24S2
|
$29,166
|
$1,167
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-24S3
|
$145,188
|
$5,808
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-24
|
$4,748,649
|
$189,946
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
1U10CA180853-01
|
$1,188,450
|
$29,711
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Integrin-targeted siRNA delivery for therapeutic gene silencing in blood cancers
|
5R01CA139444-10
|
$390,943
|
$390,943
|
SPRINGER, TIMOTHY
|
CHILDREN'S HOSPITAL CORPORATION
|
|
C-reactive protein promotes myeloma cell-mediated bone destruction
|
5R01CA138398-06
|
$348,132
|
$348,132
|
YI, QING
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Targeting Plasmacytoid Dendritic Cells to Treat Human Myeloma
|
5R01CA163881-04
|
$383,275
|
$383,275
|
YI, QING
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Multiple Myeloma and Cancer Therapies via Largazole Analogs
|
5R01CA152314-05
|
$297,051
|
$297,051
|
WILLIAMS, ROBERT
|
COLORADO STATE UNIVERSITY
|
|
Cancer Center Support Grant
|
2P30CA013696-40
|
$3,596,904
|
$35,969
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-40S1
|
$125,000
|
$1,250
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-40S2
|
$50,000
|
$500
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-40S3
|
$320,000
|
$3,200
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-40S4
|
$75,000
|
$750
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The Role of MMP13 in Multiple Myeloma Bone Disease
|
1R01CA175313-01A1
|
$346,098
|
$346,098
|
LENTZSCH, SUZANNE
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications
|
2R01CA050947-22A1
|
$301,545
|
$301,545
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
Host-tumor cell interaction in myeloma: therapeutic applications
|
5P01CA078378-15
|
$1,885,301
|
$1,885,301
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
SPORE in Multple Myeloma
|
5P50CA100707-12
|
$2,162,001
|
$2,162,001
|
ANDERSON, KENNETH
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-49S1
|
$118,825
|
$5,941
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-49S2
|
$75,000
|
$3,750
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
3P30CA006516-49S3
|
$12,500
|
$625
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
Cancer Center Support Grant
|
5P30CA006516-49
|
$10,827,666
|
$541,383
|
BENZ, EDWARD
|
DANA-FARBER CANCER INST
|
|
NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care
|
1U10CA180867-01
|
$1,302,200
|
$32,555
|
BURSTEIN, HAROLD
|
DANA-FARBER CANCER INST
|
|
Mining B-catenin/BCL9 transcriptional complex for Multiple Myeloma therapeutics
|
5R01CA151391-05
|
$335,807
|
$335,807
|
CARRASCO, RUBEN
|
DANA-FARBER CANCER INST
|
|
Dual STAT3/NF-kB Inhibitors for Targeted Cancer Therapy
|
5R01CA160979-03
|
$352,231
|
$176,116
|
FRANK, DAVID
|
DANA-FARBER CANCER INST
|
|
Stroma-mediated clonal evolution in Multiple Myeloma
|
1R01CA181683-01A1
|
$353,798
|
$353,798
|
GHOBRIAL, IRENE
|
DANA-FARBER CANCER INST
|
|
The role of miRNA15a and 16-1 in Multiple Myeloma
|
5R01CA154648-04
|
$352,231
|
$352,231
|
GHOBRIAL, IRENE
|
DANA-FARBER CANCER INST
|
|
Development and Application of Selective Covalent Cdk7 Inhibitors
|
1R01CA179483-01A1
|
$505,961
|
$505,961
|
GRAY, NATHANAEL
|
DANA-FARBER CANCER INST
|
|
Functional and biologic significance of deacetylase3 inhibition in myeloma
|
1R01CA178264-01A1
|
$353,291
|
$353,291
|
HIDESHIMA, TERU
|
DANA-FARBER CANCER INST
|
|
Integrative Oncogenomics of Multiple Myeloma
|
5P01CA155258-04
|
$1,932,302
|
$1,932,302
|
MUNSHI, NIKHIL
|
DANA-FARBER CANCER INST
|
|
Elucidating the role of microRNAs in the initiation of multiple myeloma
|
5K99CA172292-02
|
$126,228
|
$126,228
|
ZHAO, JIANJUN
|
DANA-FARBER CANCER INST
|
|
Ex vivo purging strategy for treatment of multiple myeloma
|
1R41CA179706-01A1
|
$160,632
|
$160,632
|
MCFADDEN, GRANT
|
DNATRIX, INC.
|
|
ECOG-ACRIN Operations Center
|
1U10CA180820-01
|
$13,778,655
|
$344,466
|
COMIS, ROBERT
|
ECOG-ACRIN MEDICAL RESEARCH FOUNDATION
|
|
ECOG-ACRIN Operations Center
|
3U10CA180820-01S1
|
$130,000
|
$3,250
|
COMIS, ROBERT
|
ECOG-ACRIN MEDICAL RESEARCH FOUNDATION
|
|
ECOG-ACRIN Operations Center
|
3U10CA180820-01S2
|
$81,845
|
$2,046
|
COMIS, ROBERT
|
ECOG-ACRIN MEDICAL RESEARCH FOUNDATION
|
|
ECOG-ACRIN Operations Center
|
3U10CA180820-01S3
|
$259,771
|
$6,494
|
COMIS, ROBERT
|
ECOG-ACRIN MEDICAL RESEARCH FOUNDATION
|
|
Winship Cancer Institute, National Clinical Trials Network Lead Academic Partici
|
1U10CA180864-01
|
$542,950
|
$10,859
|
RAMALINGAM, SURESH
|
EMORY UNIVERSITY
|
|
Hutchinson Center as Lead Academic Participating Site (U10)
|
1U10CA180828-01
|
$656,150
|
$32,808
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Radioimmunotherapy for Multiple Myeloma
|
5K08CA151682-05
|
$169,560
|
$169,560
|
GREEN, DAMIAN
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
CD38 Pretargeted Radioimmunotherapy for Myeloma
|
5R01CA154897-04
|
$345,117
|
$345,117
|
PRESS, OLIVER
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
ECOG Specimen Banking
|
3U24CA114737-08S1
|
$848,204
|
$212,051
|
COMIS, ROBERT
|
FRONTIER SCI & TECHNOLOGY RSCH FDN, INC
|
Total relevant funding to Multiple Myeloma for this search: $46,587,423
|